Table 2.
Residual disease activity in patients who achieved low disease activity at week 24 based on MDA, PASDAS, DAPSA, mCPDAI and GRACE and at week 52 based on MDA, PASDAS, DAPSA and GRACE
| Week 24* | Week 52† | ||||||||||
| Percentage of patients | Percentage of patients | ||||||||||
| MDA (n=172) |
PASDAS ≤3.2 (n=226) |
DAPSA ≤14 (n=251) |
mCPDAI ≤3 (n=268) |
GRACE ≤2.3 (n=201) |
Baseline measures (N=495) |
MDA (n=149) |
PASDAS ≤3.2 (n=189) |
DAPSA ≤14 (n=228) |
GRACE ≤2.3 (n=171) |
Baseline measures (N=325) |
|
| TJC >1 | 33.7 | 45.1 | 45.8 | 50.7 | 39.3 | 100.0 | 33.6 | 45.0 | 49.6 | 39.8 | 100.0 |
| SJC >1 | 20.3 | 27.9 | 24.7 | 36.2 | 22.4 | 100.0 | 12.8 | 19.0 | 19.3 | 16.4 | 100.0 |
| PASI >1 | 12.2 | 15.0 | 19.1 | 14.2 | 15.4 | 77.9 | 8.7 | 10.6 | 14.0 | 9.9 | 80.8 |
| BSA >3‡ | 8.8 | 10.7 | 13.2 | 10.9 | 11.4 | 58.4 | 2.0 | 4.8 | 7.0 | 4.1 | 60.3 |
| sPGA >1 | 7.0 | 6.6 | 9.2 | 9.0 | 7.5 | 76.7 | 3.4 | 3.7 | 5.7 | 4.7 | 79.3 |
| Pt pain VAS >15 | 16.9 | 30.1 | 37.8 | 47.8 | 27.4 | 97.7 | 18.1 | 32.8 | 43.4 | 28.7 | 97.8 |
| PtGA >20 | 7.0 | 18.6 | 25.9 | 38.1 | 14.4 | 97.3 | 6.7 | 18.0 | 30.3 | 14.0 | 98.1 |
| PGA >20 | 11.0 | 9.3 | 15.1 | 24.3 | 10.4 | 97.0 | 6.0 | 3.2 | 10.1 | 5.8 | 96.5 |
| HAQ-DI >0.5 | 19.2 | 29.6 | 37.5 | 33.6 | 23.4 | 84.0 | 15.4 | 26.5 | 36.0 | 19.3 | 83.5 |
| LEI >1 | 1.7 | 7.5 | 11.6 | 4.9 | 9.0 | 47.3 | 7.4 | 9.0 | 11.8 | 10.5 | 48.0 |
| Dactylitis >0 | 8.1 | 4.9 | 6.8 | 3.4 | 7.5 | 24.9 | 5.4 | 5.3 | 4.8 | 5.3 | 28.0 |
| CRP ≥5 mg/L | 21.5 | 22.6 | 26.3 | 22.8 | 22.9 | 58.7 | 25.5 | 25.4 | 27.6 | 26.3 | 56.8 |
| DLQI ≥3§ | 12.8 | 15.0 | 18.7 | 17.5 | 14.4 | 64.3 | − | − | − | − | 67.1 |
| SF-36 PCS >40 | 14.0 | 16.4 | 24.7 | 28.4 | 16.9 | 76.9 | 14.8 | 21.7 | 31.6 | 16.4 | 79.0 |
| SF-36 MCS >40 | 8.1 | 9.3 | 10.4 | 11.6 | 6.0 | 27.9 | 4.7 | 5.8 | 7.0 | 2.9 | 26.1 |
Observed data are reported.
*Patients initially randomised to ADA or IXE.
†Patients initially randomised to IXE.
‡One patient had a missing BSA measure at week 24.
§DLQI not collected after week 24.
ADA, adalimumab; BSA, body surface area; CRP, C reactive protein; DAPSA, Disease Activity index for Psoriatic Arthritis; DLQI, Dermatology Life Quality Index; GRACE, GRAppa Composite scorE; HAQ-DI, Health Assessment Questionnaire-Disability Index; IXE, ixekizumab; LEI, Leeds Enthesitis Index; mCPDAI, modified Composite Psoriatic Disease Activity Index; MCS, mental component summary; MDA, minimal disease activity; n, number of patients in the specified category; N, number of patients in the analysis population; PASDAS, Psoriatic Arthritis Disease Activity Score; PASI, Psoriasis Area and Severity Index; PCS, physical component summary; PGA, physician global assessment; Pt, patient; PtGA, patient global assessment; SF-36, 36-item short-form health survey; SJC, swollen joint count; sPGA, static physician global assessment; TJC, tender joint count; VAS, visual analogue scale.